<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146649</url>
  </required_header>
  <id_info>
    <org_study_id>1415301</org_study_id>
    <nct_id>NCT04146649</nct_id>
  </id_info>
  <brief_title>Effect of Therapeutic Joint Arthrocentesis on Pain and Quadriceps Function in Patients With Knee Osteoarthritis</brief_title>
  <official_title>Effect of Therapeutic Joint Arthrocentesis on Pain and Quadriceps Function in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Joint Replacement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Joint Replacement</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be prospective study of patients with knee effusion associated with degenerative
      osteoarthritis or symptomatic primary total knee arthroplasty that undergo therapeutic joint
      arthrocentesis. The diagnosis of knee osteoarthritis will be based on knee radiographs
      (including AP, Rosenburg view, lateral and Merchant views) read and interpreted by one of our
      clinical providers (PA, Fellow or Surgeon). Patients with at least Grade II Outerbridge
      changes or higher will be included in the osteoarthritis group. Patients in the arthroplasty
      group must have had a primary total knee arthroplasty without infection (as determined by
      knee aspirate) to be included. Patients will be clinically evaluated at the time of their
      visit for presence of a knee effusion using a bulge test and graded on a 4-point scale (none,
      mild, moderate, severe) which has shown good interobserver reliability (reliability
      coefficient = 0.97)23. Patients with a moderate or severe effusion will be included in the
      study. Patients with no or only mild effusion will not be included due to the increased risk
      for a dry tap or minimally effective fluid volume reduction with arthrocentesis. Patients
      having significant pain associated with their effusion will be offered a therapeutic
      arthrocentesis as part of their treatment plan discussion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quadriceps activation</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>The change in quadriceps activation prior to and post arthrocentesis will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>Self reported pain scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>Self reported function will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>Range of motion will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps Strength</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>This will be measured using the Humac Norm chair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Performance</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>This will be assessed with standardized functional tests (30 STS, TUG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Knee Synovial Fluid Aspirated</measure>
    <time_frame>Immediately post aspiration (day 0)</time_frame>
    <description>We will look at the volume of fluid drawn off the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioelectrical Impedance</measure>
    <time_frame>Immediately pre aspiration (day 0), immediately post aspiration (day 0), 7-10 days post aspiration</time_frame>
    <description>This will be measured with The RJL Systems QuantumÂ®</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Effusion Joint</condition>
  <arm_group>
    <arm_group_label>Primary Osteoarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with native knees and effusions will participate in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary TKA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with total knee replacements will participate in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthrocentesis</intervention_name>
    <description>Patients will receive a joint arthrocentesis to remove fluid from the joint.</description>
    <arm_group_label>Primary Osteoarthritis</arm_group_label>
    <arm_group_label>Primary TKA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 years or older with moderate to severe knee effusion associated with
             underlying osteoarthritis (Outerbridge grade II or higher) that undergo therapeutic
             aspiration

          2. Patients with symptomatic primary total knee arthroplasty without infection (as
             verified by prior aspiration) with moderate to severe effusion electing for
             therapeutic arthrocentesis. Must be minimum of 3 months from index surgery to be
             included.

        Exclusion Criteria:

          1. Patients with effusion related to trauma or another underlying condition (ie.
             fracture, ligamentous injury, hemarthrosis)

          2. Patients with known history of gout or with synovial fluid samples testing positive
             for urate of calcium pyrophosphate crystals

          3. Patients with knee effusion associated with septic arthritis or periprosthetic knee
             infection as determined from knee arthrocentesis.

          4. Patients with inflammatory arthritis (ie. JIA, RA, psoriatic arthritis, etc).

          5. Patients with revision knee arthroplasty, unicompartmental arthroplasty or other
             repair/reconstruction surgery

          6. Patients with underlying muscular disorder (ie. Stroke, cerebral palsy, multiple
             sclerosis, polymyalgia, fibromyalgia, muscular dystrophy, etc.)

          7. Patients with symptomatic hip pain

          8. Patients with active cancer in the area

          9. Patients with pacemakers

         10. Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Colorado Joint Replacement</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roseann Johnson</last_name>
      <phone>303-260-2940</phone>
      <email>RoseannJohnson@centura.org</email>
    </contact>
    <investigator>
      <last_name>Jason Jennings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Dennis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Kleeman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Steven-Lapsley, MPT,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bade, DPT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Carmichael, DPT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176.</citation>
    <PMID>18163497</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):421-6.</citation>
    <PMID>19407734</PMID>
  </reference>
  <reference>
    <citation>Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53. doi: 10.1016/j.joca.2013.03.018.</citation>
    <PMID>23973124</PMID>
  </reference>
  <reference>
    <citation>Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005 Mar 12-18;365(9463):965-73. Review.</citation>
    <PMID>15766999</PMID>
  </reference>
  <reference>
    <citation>Egloff C, HÃ¼gle T, Valderrabano V. Biomechanics and pathomechanisms of osteoarthritis. Swiss Med Wkly. 2012 Jul 19;142:w13583. doi: 10.4414/smw.2012.13583. eCollection 2012. Review.</citation>
    <PMID>22815119</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado Joint Replacement</investigator_affiliation>
    <investigator_full_name>Jason Jennings</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

